<p><i>Klebsiella aerogenes</i> is an opportunistic pathogen increasingly associated with healthcare-associated infections and severe respiratory complications. However, it’s in vivo adaptation during host colonization remains poorly understood. We characterized three clonal <i>K. aerogenes</i> ST93 isolates sequentially recovered on days 4, 14, and 19 of hospitalization from a patient with fatal viral pneumonia and concurrent abdominal sepsis. While initially identified generically as <i>Klebsiella</i> spp. by automated clinical systems, Whole-Genome Sequencing and Average Nucleotide Identity confirmed their identity at the species level. Genomic analysis revealed an in vivo plasmid curing event characterized by the loss of a 6.1 kb <i>bla</i><sub>OXA−232</sub>-carrying plasmid in the final isolate (18281). Despite this plasmid loss, isolate 18281 sustained persistent carbapenem resistance due to a conserved <i>ompK36</i> chromosomal mutation. Phenotypically, 18281 exhibited significantly higher lethality in <i>Galleria mellonella</i> larvae and induced progressive body weight loss in dexamethasone-treated mice compared to the other isolates. This enhanced virulence strongly correlated with a tissue-specific, compartmentalized transcriptional reprogramming, characterized by a marked 15.66-fold up-regulation of the yersiniabactin gene <i>irp1</i> within hepatic tissues, whereas the colibactin gene <i>clbA</i> was consistently downregulated in vivo across both isolates and organs. Our findings demonstrate that intra-host microevolution of <i>K. aerogenes</i> involves structural plasmid instability and targeted transcriptional remodeling during host adaptation. This localized adaptive behavior underscores the clinical threat posed by transitional clonal variants in critically ill patients undergoing viral-mediated immune dysregulation.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Genomic and phenotypic heterogeneity of Klebsiella aerogenes in a single host: plasmid loss and tissue-specific virulence gene expression during host adaptation

  • Luis Duarte-Zambrano,
  • Neli Nava-Domínguez,
  • Juan Pablo Ramírez-Hinojosa,
  • Rigoberto Hernández-Castro,
  • Nadia Rodríguez-Medina,
  • Alejandro Sánchez-Pérez,
  • Nayeli Estefania Sánchez-Casiano,
  • Michael Dunn,
  • Alejandro Alvarado-Delgado,
  • Ulises Garza-Ramos

摘要

Klebsiella aerogenes is an opportunistic pathogen increasingly associated with healthcare-associated infections and severe respiratory complications. However, it’s in vivo adaptation during host colonization remains poorly understood. We characterized three clonal K. aerogenes ST93 isolates sequentially recovered on days 4, 14, and 19 of hospitalization from a patient with fatal viral pneumonia and concurrent abdominal sepsis. While initially identified generically as Klebsiella spp. by automated clinical systems, Whole-Genome Sequencing and Average Nucleotide Identity confirmed their identity at the species level. Genomic analysis revealed an in vivo plasmid curing event characterized by the loss of a 6.1 kb blaOXA−232-carrying plasmid in the final isolate (18281). Despite this plasmid loss, isolate 18281 sustained persistent carbapenem resistance due to a conserved ompK36 chromosomal mutation. Phenotypically, 18281 exhibited significantly higher lethality in Galleria mellonella larvae and induced progressive body weight loss in dexamethasone-treated mice compared to the other isolates. This enhanced virulence strongly correlated with a tissue-specific, compartmentalized transcriptional reprogramming, characterized by a marked 15.66-fold up-regulation of the yersiniabactin gene irp1 within hepatic tissues, whereas the colibactin gene clbA was consistently downregulated in vivo across both isolates and organs. Our findings demonstrate that intra-host microevolution of K. aerogenes involves structural plasmid instability and targeted transcriptional remodeling during host adaptation. This localized adaptive behavior underscores the clinical threat posed by transitional clonal variants in critically ill patients undergoing viral-mediated immune dysregulation.